SIMCERE PHARMA Plans to Generate HKD1.554B Net Through Top-up Placing at an 8% Discount
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Source: aastocks
SIMCERE PHARMA Financial Update
- Stock Performance: SIMCERE PHARMA's stock has decreased by 6.25%, closing at HKD13.20 after a drop of HKD0.880.
- Short Selling Activity: The company has experienced significant short selling, amounting to $102.49 million, with a short selling ratio of 39.934%.
Share Placement Announcement
- Placement Details: SIMCERE PHARMA plans to issue 121 million shares, representing approximately 4.66% of its enlarged share capital, at a price of HKD12.95 per share. This price reflects an 8.03% discount compared to the previous day's closing price of HKD14.08.
- Use of Proceeds: The anticipated net proceeds from this placement are around HKD1.554 billion. About 90% of these funds will be directed towards research and development (R&D) expenses, while the remaining 10% will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and long-term growth.
Analyst Views on 02096
Wall Street analysts forecast 02096 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02096 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 11.470
Low
Averages
High
Current: 11.470
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
